Newswise — Professor Roy S. Herbst, M.D., Ph.D., Yale University, New Haven, will be recognized by The International Association for the Study of Lung Cancer with a Distinguished Award at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria, according to a release.

Herbst will accept the Paul A. Bunn Jr. Scientific Award, the release said, in honor of his scientific contributions to thoracic cancer research.

Herbst is the ensign professor of medicine, professor of pharmacology, chief of medical oncology, director of the Thoracic Oncology Research Program, and associate director for translational research at the Yale Cancer Center and Yale School of Medicine.

Herbst’s efforts over the past several decades have included bringing targeted agents to clinical trials and ultimately FDA approval; and leading clinical trials to said agents in advanced stage cancers, the release said.

“Dr. Herbst has committed his entire career to advancements in lung cancer research,” Fred R. Hirsch, M.D., Ph.D., professor of medicine and pathology at the University of Colorado Cancer Center and School of Medicine, and CEO of the IASLC, said in the release. “The IASLC is very proud to honor Dr. Herbst for his very significant contributions, which already have helped many lung cancer patients. He has made a tremendous impact across the globe and we are confident his quality work will continue to be crucial in the fight against lung cancer.”

Herbst received his bachelor’s and master’s degrees from Yale University, then earned his M.D. from Cornell University Medical College and his Ph.D. in molecular cell biology from Rockefeller University in New York, the release said. Herbst also holds a master’s degree in clinical translational research from Harvard University.

He will be honored Dec. 4 at the Opening Plenary Session at the IASLC 17th WCLC in Vienna, the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, the release said.